GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AnaptysBio Inc (NAS:ANAB) » Definitions » Degree of Operating Leverage

ANAB (AnaptysBio) Degree of Operating Leverage : -0.12 (As of Mar. 2025)


View and export this data going back to 2017. Start your Free Trial

What is AnaptysBio Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. AnaptysBio's Degree of Operating Leverage for the quarter that ended in Mar. 2025 was -0.12. The higher Degree of Operating Leverage, the higher operating risk the company will take.

The industry rank for AnaptysBio's Degree of Operating Leverage or its related term are showing as below:

ANAB's Degree of Operating Leverage is ranked better than
54.79% of 887 companies
in the Biotechnology industry
Industry Median: -0.02 vs ANAB: -0.12

AnaptysBio Degree of Operating Leverage Historical Data

The historical data trend for AnaptysBio's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AnaptysBio Degree of Operating Leverage Chart

AnaptysBio Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Degree of Operating Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.09 -11.59 -1.09 0.53 -0.08

AnaptysBio Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 0.11 -0.01 -0.08 -0.12

Competitive Comparison of AnaptysBio's Degree of Operating Leverage

For the Biotechnology subindustry, AnaptysBio's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AnaptysBio's Degree of Operating Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AnaptysBio's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where AnaptysBio's Degree of Operating Leverage falls into.


;
;

AnaptysBio Degree of Operating Leverage Calculation

AnaptysBio's Degree of Operating Leverage for the quarter that ended in Mar. 2025 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( -78.746 (Mar. 2025) / -143.24 (Mar. 2024) - 1 )/( 111.872 (Mar. 2025) / 22.962 (Mar. 2024) - 1 )
=-0.4503/3.872
=-0.12***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


AnaptysBio  (NAS:ANAB) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


AnaptysBio Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of AnaptysBio's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


AnaptysBio Business Description

Industry
Traded in Other Exchanges
Address
10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Executives
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Hollings Renton director
Paul F. Lizzul officer: Chief Medical Officer 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Eric J Loumeau officer: General Counsel C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121
Dennis Mulroy officer: Chief Financial Officer
Dennis M Fenton director
Daniel Faga director 3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
John A Orwin director C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Rita Jain director C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Hamza Suria director, officer: President, CEO C/O ANAPTYSBIO, INC., 10421 PACIFIC CENTER COURT, SUITE 200, SAN DIEGO CA 92121
Oleg Nodelman director, 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Magda Marquet director ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121
J. Anthony Ware director C/O ANAPTYSBIO, INC., 10421 PACIFIC CENTER COURT, SUITE 200, SAN DIEGO CA 92121
Laura Hamill director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Marco Londei officer: Chief Medical Officer C/O ANAPTYSBIO, INC., 10421 PACIFIC CENTER COURT, SUITE 200, SAN DIEGO CA 92121